Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Brokerages

Key Points

• Trevi Therapeutics has received a consensus rating of "Buy" from analysts, with an average target price of $20.3750, indicating strong investor interest in the stock.
• Recent institutional trading shows significant increases in holdings by major investors, with 95.76% of shares currently owned by institutional investors.
• The company reported better-than-expected quarterly earnings, posting an EPS of ($0.09), surpassing the consensus estimate of ($0.10).

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned a consensus rating of "Buy" from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $20.3750.

A number of research firms have recently issued reports on TRVI. HC Wainwright initiated coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $21.00 price target on the stock. Oppenheimer reissued an "outperform" rating on shares of Trevi Therapeutics in a report on Monday, June 2nd. Wall Street Zen cut Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. Needham & Company LLC reduced their price target on shares of Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Finally, Cantor Fitzgerald assumed coverage on shares of Trevi Therapeutics in a research note on Tuesday, July 1st. They issued an "overweight" rating and a $25.00 price objective on the stock.

Institutional Trading of Trevi Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Persistent Asset Partners Ltd increased its stake in shares of Trevi Therapeutics by 3.3% in the second quarter. Persistent Asset Partners Ltd now owns 42,788 shares of the company's stock worth $234,000 after purchasing an additional 1,384 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Trevi Therapeutics by 10.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,925 shares of the company's stock worth $113,000 after buying an additional 1,627 shares in the last quarter. American Century Companies Inc. increased its stake in Trevi Therapeutics by 2.1% during the first quarter. American Century Companies Inc. now owns 79,796 shares of the company's stock worth $502,000 after acquiring an additional 1,653 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of Trevi Therapeutics by 20.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 12,000 shares of the company's stock valued at $66,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Summit Investment Advisors Inc. increased its position in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after acquiring an additional 2,894 shares during the last quarter. Institutional investors own 95.76% of the company's stock.

Trevi Therapeutics Stock Performance

Shares of Trevi Therapeutics stock traded down $0.04 during trading on Friday, hitting $7.41. The company's stock had a trading volume of 364,802 shares, compared to its average volume of 1,812,109. Trevi Therapeutics has a 52 week low of $2.36 and a 52 week high of $8.11. The company has a market capitalization of $902.39 million, a PE ratio of -17.64 and a beta of 0.58. The company has a fifty day simple moving average of $6.69 and a two-hundred day simple moving average of $6.09.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. As a group, analysts predict that Trevi Therapeutics will post -0.49 EPS for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.